BioPlus Acquisition is a shell companies business based in the US. BioPlus Acquisition shares (BIOS) are listed on the NASDAQ and all prices are listed in US Dollars.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| 52-week range | $0.00 - $0.00 |
|---|---|
| 50-day moving average | $10.77 |
| 200-day moving average | $10.55 |
| Wall St. target price | $20.00 |
| PE ratio | 51.4048 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.21 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing BioPlus Acquisition stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BioPlus Acquisition's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
BioPlus Acquisition's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 51x. In other words, BioPlus Acquisition shares trade at around 51x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -0.72% |
| Return on equity TTM | 0% |
| Profit margin | 0% |
| Book value | $-0.86 |
| Market Capitalization | $209.1 million |
TTM: trailing 12 months
We're not expecting BioPlus Acquisition to pay a dividend over the next 12 months.
BioPlus Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the life sciences industry. BioPlus Acquisition Corp. was incorporated in 2021 and is based in New York, New York. .
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.